Pages that link to "Q41487713"

The following pages link to Expression of an F1/V fusion protein in attenuatedSalmonella typhimuriumand protection of mice against plague (Q41487713):

Displaying 44 items.

• Plague Vaccine Development: Current Research and Future Trends (Q28066875) (← links)
• Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization (Q33577674) (← links)
• Immune defense against pneumonic plague (Q33584403) (← links)
• Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. (Q33612949) (← links)
• Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice (Q33613422) (← links)
• Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice (Q33635050) (← links)
• Evaluation of YadC protein delivered by live attenuated Salmonella as a vaccine against plague (Q33637474) (← links)
• Human immune response to a plague vaccine comprising recombinant F1 and V antigens (Q33788286) (← links)
• Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost (Q33824782) (← links)
• Structural and functional significance of the FGL sequence of the periplasmic chaperone Caf1M of Yersinia pestis. (Q33991743) (← links)
• Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques (Q34290878) (← links)
• Vaccination against bubonic and pneumonic plague (Q34310210) (← links)
• Yersinia pestis (plague) vaccines (Q34324211) (← links)
• Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis (Q34334406) (← links)
• Intranasal vaccination against plague, tetanus and diphtheria (Q34343294) (← links)
• Vaccines for Category A bioterrorism diseases (Q35040844) (← links)
• Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion (Q35113336) (← links)
• Advances in the development of bacterial vector technology (Q35193532) (← links)
• Protection against pneumonic plague following oral immunization with a non-replicating vaccine (Q36099515) (← links)
• A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen (Q36237899) (← links)
• Acquisition of maternal antibodies both from the placenta and by lactation protects mouse offspring from Yersinia pestis challenge (Q36378660) (← links)
• Interaction between Yersinia pestis and the host immune system (Q36594020) (← links)
• Current challenges in the development of vaccines for pneumonic plague (Q36628038) (← links)
• Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates (Q37051021) (← links)
• Technical transformation of biodefense vaccines (Q37058898) (← links)
• Developing live vaccines against plague. (Q37599376) (← links)
• Prospects for new plague vaccines. (Q37640118) (← links)
• Live-attenuated Yersinia pestis vaccines (Q38113270) (← links)
• The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague (Q38589273) (← links)
• Plague Vaccines: Status and Future (Q38813137) (← links)
• Immunology of Yersinia pestis Infection (Q40512106) (← links)
• Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates (Q41418787) (← links)
• Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. (Q41428963) (← links)
• Purification and characterization of a recombinant Yersinia pestis V-F1 “Reversed” fusion protein for use as a new subunit vaccine against plague (Q41431425) (← links)
• Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis (Q41452700) (← links)
• Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes (Q41453072) (← links)
• A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice (Q41462360) (← links)
• Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague (Q41466529) (← links)
• Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6. (Q41470183) (← links)
• Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine (Q41485426) (← links)
• Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. (Q50026293) (← links)
• A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066). (Q50076202) (← links)
• Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii (Q50091926) (← links)
• Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. (Q55361721) (← links)